Tafamidis is the only FDA-approved treatment for TTR amyloidosis, a TTR stabilizer demonstrated in the ATTR-ACT trial to decrease mortality and cardiovascular hospitalizations. The gene discussed is TTR; the disease is familial amyloid neuropathy.